FindTrial
Sign In

A novel immunotherapy strategy for triple-negative breast cancer based on engineered macrophages

A novel immunotherapy strategy for triple-negative breast cancer based on engineered macrophages

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120664
Enrollment
Unknown
Registered
2026-03-18
Start date
2026-03-18
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Triple-negative breast cancer

Interventions

Observation group:none

Sponsors

The Second Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with triple-negative breast cancer and whose specimens were analyzed pathologically at this hospital, aged 18-80 years.

Exclusion criteria

Exclusion criteria: Specimens from patients with tumors in other parts.

Design outcomes

Primary

MeasureTime frame
CD8+ T cell;ECM markers (a-SMA and FN);—

Countries

China

Contacts

Public ContactChen Mengchun

The Second Affiliated Hospital of Wenzhou Medical University

cmcwzmc@163.com+86 577 8567 6582

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026